Overview A Phase 1 Study of JSP191 (Briquilimab) in Subjects With LR-MDS Status: Recruiting Trial end date: 2025-07-01 Target enrollment: Participant gender: Summary A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy. Phase: Phase 1 Details Lead Sponsor: Jasper Therapeutics, Inc.